Post-Cardiac Arrest Syndrome Market, PCAS Epidemiology, Leading companies and pipeline

Albany, California Feb 14, 2019 (Issuewire.com)  - There were approximately 1,150,165 diagnosed incident cases of sudden cardiac arrest (SCA) in 2016 in 7 major markets.

• In 2016, 103,374 SCA cases has gained ROSC (return of the spontaneous circulation) out of which 77,530 were ROSC-Comatose cases at the time of hospital admission in the United States.
• In 2016, the incident cases of IHSCA (In Hospital Sudden Cardiac Arrest) and OHSCA (Out of Hospital Sudden Cardiac Arrest) in Japan was found to be 72,117 and 123,000.
• Among the European countries, Germany had the highest diagnosed incident cases of Sudden Cardiac Arrest with 148,438 cases, followed by the United Kingdom which had diagnosed incident.

(Albany, US) DelveInsight launched a new report on Post-Cardiac Arrest Syndrome (PCAS) - Market Insights, Epidemiology and Market Forecast-2027

Key topics covered

• The report covers PCAS treatment algorithms and Post-Cardiac Arrest Syndrome treatment guidelines for US, EU5, and Japan.
• It provides the insights about PCAS historical and current patient pool and forecasted trend for seven major markets.
• This report encloses the detailed analysis of PCAS marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. 
• The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
• The PCAS market report gives the thorough understanding of the PCAS

“Approximately, two third of the PCAS associated mortality are because of brain injury and it contributes significantly to life time disability in remaining survived patients.”

The Post-Cardiac Arrest Syndrome market analysis carried out for the period of 2016-2027 demonstrates that the market size of Post-Cardiac Arrest Syndrome was found out to be USD 547.0 Million in 2016 in 7MM. The United States accounts for the largest market size of Post-Cardiac Arrest Syndrome, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 At present, there is no therapy approved for the treatment/prevention of PCAS and the current standard of neuroprotection is targeted temperature management and controlled Oxygenation. The current treatment approach has shown good results in many cases but still unable to reduce the mortality incidences.

 NeuroproteXeon/Mallinckrodt is developing Xenon gas as an add on therapy with current standard of neuroprotectants to counter the post cardiac arrest brain injury associated mortality. In the upcoming years, Xenex (Xenon gas + Delivery system) is anticipated to dominate the 2027 market of PCAS and is expected to hold decent market share.

Post-Cardiac Arrest Syndrome Companies covered 

• NeuroproteXeon
• Mallinckrodt

And  many others

       Drugs covered

• Xenon

And many others

Table of contents

• Key Insights
• Post-Cardiac Arrest Syndrome Market Overview at a Glance
• Disease Overview: PCAS
• Post-Cardiac Arrest Syndrome Epidemiology and Patient Population
• Country Wise- Post-Cardiac Arrest Syndrome Epidemiology
  5.1.      United States
  5.2.      Germany
  5.3.      France
  5.4.      Italy
  5.5.      Spain
  5.6.      United Kingdom
  5.7.      Japan
• Current Post-Cardiac Arrest Syndrome Treatment Practices

6.1.      American Heart Association Guidelines
6.2.      European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015
6.3.      Japan Resuscitation Council Resuscitation Guidelines 2015

• Post-Cardiac Arrest Syndrome Unmet Needs
• Post-Cardiac Arrest Syndrome Emerging Therapies

8.1.      Xenon: NeuroproteXeon/ Mallinckrodt

• PCAS: 7 Major Market Analysis

9.1.      Key Findings
9.2.      Market Size of Post-Cardiac Arrest Syndrome in 7MM

• Market Outlook by Country
• The United States: Market Outlook

11.1.    United States Market Size
11.3.    Germany Market Size
11.4.    France Market Size
11.5.    Italy Market Size
11.6.    The United Kingdom Market Size
11.7.    Spain Market Size
11.8.    Japan: Market Outlook
11.9.    Japan Market Size

• Post-Cardiac Arrest Syndrome Market Drivers
• Post-Cardiac Arrest Syndrome Market Barriers
• Appendix
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur

info@delveinsight.com

+919650213330

SOURCE DelveInsight

Media Contact

Delveinsight Business Reserarch LLP info@delveinsight.com +19193216187 304 S. Jones Blvd #2432, Las Vegas NV 89107 https://www.delveinsight.com/